Applied Therapeutics, INC Form 4 insider transactions

A director of Applied Therapeutics, Inc. reported changes in beneficial ownership following the company's merger, converting shares and options into cash and contingent value rights.

Applied Therapeutics' Chief Commercial Officer, Corwin Dale Hooks, disposed of all common stock holdings following the company's merger, receiving cash and contingent value rights.

Applied Therapeutics' COO, Constantine Chinoporos, reported the disposition of all his common stock and RSUs following the company's merger with Cycle Group Holdings Limited.

Applied Therapeutics director Jay S. Skyler reports zero beneficial ownership of common stock and options following the company's merger with Cycle Group Holdings Limited and AT2B, INC.

Applied Therapeutics' CFO Leslie D. Funtleyder reported significant share and option dispositions following the company's merger with AT2B, INC., receiving $0.088 per share plus a contingent value right.

Applied Therapeutics' Chief Medical Officer, Evan Prescott Bailey, disposed of all common stock and had out-of-the-money stock options cancelled as part of the company's merger with Cycle Group Holdings Limited.

Applied Therapeutics Director Teena Lerner reported the disposition of all her common stock and out-of-the-money stock options following the company's merger with AT2B, Inc.

Applied Therapeutics' Chief Financial Officer, Leslie D. Funtleyder, was granted 150,000 Restricted Stock Units (RSUs) vesting over a two-year period.

A director at Applied Therapeutics, Stacy J. Kanter, sold 43,000 shares of common stock at an average price of $0.112 per share.

Applied Therapeutics' CFO, Leslie D. Funtleyder, was granted 150,000 Restricted Stock Units, increasing total beneficial ownership to 1,190,459 shares after correcting a prior administrative error.

Applied Therapeutics, Inc. disclosed that Leslie D. Funtleyder, Director, CFO, and Interim CEO, was granted 300,000 Restricted Stock Units and reported a correction to previously overstated beneficial ownership.

Applied Therapeutics, Inc.'s Chief Medical Officer, Evan Prescott Bailey, was granted 300,000 compensatory Restricted Stock Units, vesting over time, as disclosed in a recent SEC Form 4 filing.

Applied Therapeutics, Inc. Director Teena Lerner was granted 200,000 stock options with an exercise price of $0.395, vesting over 36 months.

Applied Therapeutics, Inc. director Stacy J. Kanter was granted 200,000 stock options with an exercise price of $0.395, vesting over 36 months.

Applied Therapeutics, Inc. (APLT) Director Jay S. Skyler was granted 200,000 stock options with an exercise price of $0.395, vesting over 36 months.

Corwin Dale Hooks, Chief Commercial Officer of Applied Therapeutics, Inc., reports the acquisition of 250,000 shares and disposal of 550,000 shares of common stock on March 24, 2025, according to a Form 4 filing with the SEC.

Leslie D. Funtleyder, Interim CEO and CFO of Applied Therapeutics, acquired 350,000 Restricted Stock Units (RSUs) on March 24, 2025, according to a Form 4 filing.

Constantine Chinoporos, COO of Applied Therapeutics, was granted 350,000 Restricted Stock Units (RSUs) on March 24, 2025, under the company's 2019 Equity Incentive Plan.

Riccardo Perfetti, Chief Medical Officer of Applied Therapeutics, sold 10,366 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Leslie D. Funtleyder, Interim CEO and CFO of Applied Therapeutics, sold 14,502 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Constantine Chinoporos, an officer at Applied Therapeutics, sold 447 shares of common stock on March 4, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Leslie D. Funtleyder, Interim CEO and CFO of Applied Therapeutics, sold shares to cover tax withholding obligations related to vesting of restricted stock units.

Riccardo Perfetti, Chief Medical Officer of Applied Therapeutics, sold 86,078 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Constantine Chinoporos, Chief Operating Officer and Chief Business Officer of Applied Therapeutics, sold 28,117 shares of common stock to cover tax withholding obligations related to vesting of restricted stock units.

John Johnson, Executive Chairman of Applied Therapeutics, Inc., was granted 500,000 restricted stock units and 1,000,000 stock options as compensation.

Leslie D. Funtleyder, interim CEO of Applied Therapeutics, received 150,000 shares of restricted stock units and 150,000 stock options as part of his compensation.

Leslie D. Funtleyder, CFO of Applied Therapeutics, Inc., sold 13,530 shares of common stock on August 22, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.

Riccardo Perfetti, Chief Medical Officer of Applied Therapeutics, sold 22,681 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Applied Therapeutics CEO Shoshana Shendelman reports the disposition of shares through sales and a trust distribution.

Applied Therapeutics CEO Shoshana Shendelman sold shares to cover tax withholding obligations related to the vesting and settlement of compensatory Restricted Stock Units.